Compare Stocks

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CING Cingulate	$0.88 +3.5%	$1.10	$0.75 ▼ $23.80	$4.41M	-0.95	325,680 shs	43,767 shs
CYCC Cyclacel Pharmaceuticals	$1.85 -5.6%	$2.35	$1.52 ▼ $13.20	$2.44M	0.54	133,567 shs	37,739 shs
IMNN Imunon	$1.13 -0.9%	$1.03	$0.48 ▼ $2.00	$10.72M	2.03	193,212 shs	195,960 shs
VBLT Vascular Biogenics	$5.46 -8.8%	$0.40	$0.10 ▼ $6.74	$423.91M	0.77	2.19 million shs	161,505 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CING Cingulate	+0.69%	-8.04%	-18.52%	-80.53%	-95.77%
CYCC Cyclacel Pharmaceuticals	-5.13%	-4.64%	-21.28%	-12.32%	-81.86%
IMNN Imunon	-1.32%	-26.95%	+39.58%	+88.13%	-17.13%
VBLT Vascular Biogenics	0.00%	0.00%	0.00%	0.00%	+2,547.91%

New crypto project uncovers 2,050% in 65 days (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CING Cingulate	2.2781 of 5 stars	3.2	4.0	0.0	0.0	1.3	4.2	0.0
CYCC Cyclacel Pharmaceuticals	1.2633 of 5 stars	3.3	5.0	0.0	0.0	0.0	0.0	0.6
IMNN Imunon	1.978 of 5 stars	3.5	4.0	0.0	0.0	1.1	0.0	1.3
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CING Cingulate	2.33	Hold	$8.00	809.09% Upside
CYCC Cyclacel Pharmaceuticals	2.50	Moderate Buy	$21.00	1,035.14% Upside
IMNN Imunon	3.00	Buy	$13.00	1,055.56% Upside
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest VBLT, CYCC, IMNN, and CING Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/1/2024	IMNN Imunon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $13.00
3/13/2024	IMNN Imunon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CING Cingulate	N/A	N/A	N/A	N/A	($5.88) per share	N/A
CYCC Cyclacel Pharmaceuticals	$420K	5.81	N/A	N/A	$0.57 per share	3.25
IMNN Imunon	$500K	21.15	N/A	N/A	$1.42 per share	0.79
VBLT Vascular Biogenics	$660K	642.29	N/A	N/A	$0.32 per share	17.06

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CING Cingulate	-$23.53M	-$32.60	N/A	∞	N/A	N/A	N/A	-432.81%	5/8/2024 (Estimated)
CYCC Cyclacel Pharmaceuticals	-$22.56M	-$27.22	N/A	N/A	N/A	N/A	-448.19%	-151.29%	5/9/2024 (Estimated)
IMNN Imunon	-$19.51M	-$2.18	N/A	N/A	N/A	N/A	-98.04%	-66.49%	5/9/2024 (Estimated)
VBLT Vascular Biogenics	-$32.30M	-$0.21	N/A	∞	N/A	N/A	-73.45%	-54.11%	N/A

Latest VBLT, CYCC, IMNN, and CING Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/19/2024	Q4 2023	CYCC Cyclacel Pharmaceuticals	-$6.35	-$6.23	+$0.12	-$6.23	N/A	$0.03 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CING Cingulate	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMNN Imunon	N/A	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CING Cingulate	N/A	0.06	0.06
CYCC Cyclacel Pharmaceuticals	N/A	0.91	0.91
IMNN Imunon	N/A	2.47	2.47
VBLT Vascular Biogenics	N/A	4.63	4.63

Ownership

Institutional Ownership

Company	Institutional Ownership
CING Cingulate	41.31%
CYCC Cyclacel Pharmaceuticals	23.58%
IMNN Imunon	4.47%
VBLT Vascular Biogenics	0.96%

Insider Ownership

Company	Insider Ownership
CING Cingulate	38.43%
CYCC Cyclacel Pharmaceuticals	8.47%
IMNN Imunon	3.84%
VBLT Vascular Biogenics	6.13%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CING Cingulate	15	5.01 million	3.09 million	Not Optionable
CYCC Cyclacel Pharmaceuticals	2,018	1.32 million	1.21 million	Optionable
IMNN Imunon	31	9.40 million	9.04 million	Not Optionable
VBLT Vascular Biogenics	7	77.64 million	72.88 million	Optionable

VBLT, CYCC, IMNN, and CING Headlines

Source	Headline
	Tommy Garten elected to VBL Hall of Fame therecorderonline.com - March 28 at 1:31 PM
	Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system nature.com - February 21 at 3:29 PM
	Vascular News and Research news-medical.net - November 25 at 2:28 PM
	Vascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26 msn.com - November 3 at 12:39 AM
	Notable Labs Closes Merger Transaction With VBL Therapeutics finance.yahoo.com - October 16 at 3:55 PM
	VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting finance.yahoo.com - October 12 at 3:13 PM
	VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting finance.yahoo.com - October 4 at 8:40 AM
	Vascular Biogenics Rises on Presentation Hype finance.yahoo.com - September 9 at 12:00 PM
	VBLT Stock Sees Decline of Approximately -0.22% in Last Five Days knoxdaily.com - September 7 at 9:15 PM
	VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC finance.yahoo.com - September 6 at 7:30 PM
	VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT businesswire.com - August 28 at 7:00 PM
	VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT businesswire.com - August 28 at 3:04 PM
	VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - August 14 at 8:09 AM
	Monitoring Vascular Biogenics Ltd. (VBLT) after recent insider movements knoxdaily.com - July 26 at 4:10 PM
	Vascular Biogenics (NASDAQ: VBLT) fool.com - July 23 at 5:52 PM
	Recent Insider Activity Suggests Potential Gains for Vascular Biogenics Ltd. (VBLT) knoxdaily.com - July 12 at 4:20 PM
	VBLT Stock Sees Decline of Approximately -4.31% in Last Five Days knoxdaily.com - July 7 at 2:11 PM
	Days-to-cover ratio for VBLT surges to 0.84 due to rise in short interest knoxdaily.com - June 23 at 8:26 PM
	The Role of Peripheral Arterial Disease in the Pathogenesis of Diabetic Foot Disease: When to Refer for Vascular Surgery medscape.com - May 18 at 1:35 AM
	VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - May 15 at 8:03 PM
	Developing a Patient-Centered Approach to Vascular Access Device Selection medscape.com - May 10 at 8:52 AM
	CADASIL: The Most Common Hereditary Subcortical Vascular Dementia medscape.com - May 5 at 1:05 AM
	Aspirin in Stroke Prevention in Nonvalvular Atrial Fibrillation and Stable Vascular Disease medscape.com - May 2 at 8:00 PM
	Vascular Biogenics Stock (NASDAQ:VBLT), Dividends benzinga.com - April 4 at 1:52 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cingulate

NASDAQ:CING

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Cyclacel Pharmaceuticals

NASDAQ:CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Imunon

NASDAQ:IMNN

Imunon, Inc., a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies, such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Vascular Biogenics

NASDAQ:VBLT

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial